Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GSK Plays Down Seretide/Advair Generic Launch In U.K., But Pressure Builds

This article was originally published in The Pink Sheet Daily

Executive Summary

Mylan’s launch in the U.K. of the first generic version of anti-asthma drug Seretide (Advair in the U.S.) has been a long-time coming -- and the copycat version has key differences from the original -- but the event underscores building pressures on GSK’s respiratory franchise.


Related Content

Breo Ellipta Stumbles On Pediatric Asthma Claim, But Advair Helps Break The Fall


Related Companies